NLS Other Assets vs Non Currrent Assets Other Analysis

NLSP Stock

USD 0.16 0.01 6.67%

NLS Pharmaceutics financial indicator trend analysis is infinitely more than just investigating NLS Pharmaceutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NLS Pharmaceutics is a good investment. Please check the relationship between NLS Pharmaceutics Other Assets and its Non Currrent Assets Other accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NLS Pharmaceutics AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

Other Assets vs Non Currrent Assets Other

Other Assets vs Non Currrent Assets Other Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NLS Pharmaceutics Other Assets account and Non Currrent Assets Other. At this time, the significance of the direction appears to have almost no relationship.

The correlation between NLS Pharmaceutics' Other Assets and Non Currrent Assets Other is 0.14. Overlapping area represents the amount of variation of Other Assets that can explain the historical movement of Non Currrent Assets Other in the same time period over historical financial statements of NLS Pharmaceutics AG, assuming nothing else is changed. The correlation between historical values of NLS Pharmaceutics' Other Assets and Non Currrent Assets Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Assets of NLS Pharmaceutics AG are associated (or correlated) with its Non Currrent Assets Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Currrent Assets Other has no effect on the direction of Other Assets i.e., NLS Pharmaceutics' Other Assets and Non Currrent Assets Other go up and down completely randomly.

Correlation Coefficient

0.14

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Other Assets

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.

Most indicators from NLS Pharmaceutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NLS Pharmaceutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NLS Pharmaceutics AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

As of 05/18/2024, Enterprise Value is likely to grow to about 28.5 M, while Selling General Administrative is likely to drop 5,562.

NLS Pharmaceutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital
Total Assets		-0.57	0.2	0.27	0.96	0.59	0.93	-0.88	-0.88	0.4	1.0	-0.25	-0.26	-0.34	-0.59	1.0	-0.48	0.74	0.77	-0.57	0.84	0.94	-0.76	0.66	1.0	0.84
Short Long Term Debt Total	-0.57		0.3	-0.84	-0.7	-0.97	-0.71	0.87	0.85	-0.9	-0.51	-0.44	-0.4	-0.3	1.0	-0.51	0.64	-0.89	-0.32	0.99	-0.66	-0.79	0.83	0.22	-0.52	-0.1
Other Current Liab	0.2	0.3		-0.74	0.22	-0.32	0.24	0.01	0.04	-0.65	0.27	-0.96	-0.97	0.11	0.32	0.27	0.06	-0.18	0.55	0.31	0.11	0.04	-0.22	0.67	0.26	0.62
Total Current Liabilities	0.27	-0.84	-0.74		0.33	0.8	0.3	-0.57	-0.59	0.98	0.2	0.82	0.79	0.19	-0.84	0.2	-0.52	0.73	-0.07	-0.84	0.34	0.52	-0.42	-0.52	0.2	-0.29
Total Stockholder Equity	0.96	-0.7	0.22	0.33		0.72	0.99	-0.96	-0.94	0.48	0.96	-0.22	-0.24	-0.17	-0.72	0.96	-0.58	0.8	0.79	-0.71	0.9	0.97	-0.9	0.54	0.96	0.78
Other Liab	0.59	-0.97	-0.32	0.8	0.72		0.73	-0.88	-0.85	0.89	0.54	0.43	0.4	0.21	-0.97	0.54	-0.57	0.9	0.41	-0.97	0.76	0.78	-0.83	-0.17	0.55	0.15
Net Tangible Assets	0.93	-0.71	0.24	0.3	0.99	0.73		-0.95	-0.92	0.45	0.92	-0.23	-0.25	-0.14	-0.72	0.92	-0.57	0.78	0.78	-0.72	0.92	0.94	-0.93	0.51	0.92	0.76
Net Debt	-0.88	0.87	0.01	-0.57	-0.96	-0.88	-0.95		0.99	-0.7	-0.86	-0.05	-0.03	0.04	0.88	-0.86	0.64	-0.89	-0.66	0.88	-0.89	-0.97	0.93	-0.28	-0.86	-0.56
Retained Earnings	-0.88	0.85	0.04	-0.59	-0.94	-0.85	-0.92	0.99		-0.71	-0.85	-0.07	-0.04	0.1	0.87	-0.85	0.71	-0.88	-0.68	0.87	-0.89	-0.97	0.89	-0.29	-0.86	-0.55
Accounts Payable	0.4	-0.9	-0.65	0.98	0.48	0.89	0.45	-0.7	-0.71		0.33	0.73	0.7	0.19	-0.91	0.33	-0.55	0.82	0.09	-0.91	0.49	0.63	-0.56	-0.41	0.34	-0.15
Cash	1.0	-0.51	0.27	0.2	0.96	0.54	0.92	-0.86	-0.85	0.33		-0.32	-0.33	-0.35	-0.54	1.0	-0.45	0.7	0.8	-0.52	0.83	0.92	-0.75	0.71	1.0	0.88
Non Current Assets Total	-0.25	-0.44	-0.96	0.82	-0.22	0.43	-0.23	-0.05	-0.07	0.73	-0.32		1.0	0.17	-0.44	-0.32	-0.09	0.26	-0.56	-0.43	-0.13	-0.03	0.12	-0.81	-0.31	-0.71
Non Currrent Assets Other	-0.26	-0.4	-0.97	0.79	-0.24	0.4	-0.25	-0.03	-0.04	0.7	-0.33	1.0		0.14	-0.4	-0.33	-0.03	0.23	-0.58	-0.38	-0.15	-0.06	0.16	-0.8	-0.32	-0.7
Other Assets	-0.34	-0.3	0.11	0.19	-0.17	0.21	-0.14	0.04	0.1	0.19	-0.35	0.17	0.14		-0.24	-0.35	0.06	0.09	-0.16	-0.24	-0.26	-0.14	-0.16	-0.56	-0.34	-0.43
Long Term Debt	-0.59	1.0	0.32	-0.84	-0.72	-0.97	-0.72	0.88	0.87	-0.91	-0.54	-0.44	-0.4	-0.24		-0.54	0.67	-0.9	-0.33	1.0	-0.68	-0.81	0.83	0.19	-0.54	-0.12
Cash And Short Term Investments	1.0	-0.51	0.27	0.2	0.96	0.54	0.92	-0.86	-0.85	0.33	1.0	-0.32	-0.33	-0.35	-0.54		-0.45	0.7	0.8	-0.52	0.83	0.92	-0.75	0.71	1.0	0.88
Net Receivables	-0.48	0.64	0.06	-0.52	-0.58	-0.57	-0.57	0.64	0.71	-0.55	-0.45	-0.09	-0.03	0.06	0.67	-0.45		-0.66	-0.42	0.71	-0.6	-0.66	0.69	-0.02	-0.46	-0.19
Common Stock Total Equity	0.74	-0.89	-0.18	0.73	0.8	0.9	0.78	-0.89	-0.88	0.82	0.7	0.26	0.23	0.09	-0.9	0.7	-0.66		0.56	-0.9	0.78	0.89	-0.84	0.05	0.71	0.34
Common Stock Shares Outstanding	0.77	-0.32	0.55	-0.07	0.79	0.41	0.78	-0.66	-0.68	0.09	0.8	-0.56	-0.58	-0.16	-0.33	0.8	-0.42	0.56		-0.37	0.83	0.69	-0.71	0.71	0.8	0.82
Non Current Liabilities Total	-0.57	0.99	0.31	-0.84	-0.71	-0.97	-0.72	0.88	0.87	-0.91	-0.52	-0.43	-0.38	-0.24	1.0	-0.52	0.71	-0.9	-0.37		-0.71	-0.8	0.84	0.2	-0.53	-0.11
Other Current Assets	0.84	-0.66	0.11	0.34	0.9	0.76	0.92	-0.89	-0.89	0.49	0.83	-0.13	-0.15	-0.26	-0.68	0.83	-0.6	0.78	0.83	-0.71		0.85	-0.86	0.44	0.83	0.65
Other Stockholder Equity	0.94	-0.79	0.04	0.52	0.97	0.78	0.94	-0.97	-0.97	0.63	0.92	-0.03	-0.06	-0.14	-0.81	0.92	-0.66	0.89	0.69	-0.8	0.85		-0.88	0.4	0.93	0.65
Total Liab	-0.76	0.83	-0.22	-0.42	-0.9	-0.83	-0.93	0.93	0.89	-0.56	-0.75	0.12	0.16	-0.16	0.83	-0.75	0.69	-0.84	-0.71	0.84	-0.86	-0.88		-0.25	-0.76	-0.54
Net Invested Capital	0.66	0.22	0.67	-0.52	0.54	-0.17	0.51	-0.28	-0.29	-0.41	0.71	-0.81	-0.8	-0.56	0.19	0.71	-0.02	0.05	0.71	0.2	0.44	0.4	-0.25		0.7	0.95
Total Current Assets	1.0	-0.52	0.26	0.2	0.96	0.55	0.92	-0.86	-0.86	0.34	1.0	-0.31	-0.32	-0.34	-0.54	1.0	-0.46	0.71	0.8	-0.53	0.83	0.93	-0.76	0.7		0.88
Net Working Capital	0.84	-0.1	0.62	-0.29	0.78	0.15	0.76	-0.56	-0.55	-0.15	0.88	-0.71	-0.7	-0.43	-0.12	0.88	-0.19	0.34	0.82	-0.11	0.65	0.65	-0.54	0.95	0.88

Click cells to compare fundamentals

NLS Pharmaceutics Account Relationship Matchups

NLS Pharmaceutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	696.4K	1.2M	5.8M	9.3M	10.7M	11.2M
Other Current Liab	835.7K	(2.5B)	666.4K	986.4K	887.8K	932.2K
Total Current Liabilities	4.0M	7.2M	2.4M	3.4M	3.9M	3.7M
Total Stockholder Equity	(6.2M)	(9.0M)	542.4K	3.3M	3.8M	4.0M
Other Liab	159.0K	2.7M	2.7M	2.8M	3.2M	1.9M
Net Tangible Assets	(8.8M)	(6.2M)	(9.0M)	542.4K	623.7K	654.9K
Net Debt	621.9K	2.0M	(5.4M)	(8.9M)	(8.1M)	(7.7M)
Retained Earnings	(26.9M)	(29.8M)	(41.7M)	(58.2M)	(52.4M)	(49.8M)
Accounts Payable	2.5M	4.0M	1.7M	2.4M	2.7M	2.3M
Cash	220.3K	93.7K	5.4M	8.9M	10.3M	10.8M
Non Current Assets Total	314.7K	1.0M	41.6K	30.2K	34.8K	33.0K
Non Currrent Assets Other	260.2K	946.9K	12.0K	12.1K	14.0K	13.3K
Cash And Short Term Investments	220.3K	93.7K	5.4M	8.9M	10.3M	10.8M
Net Receivables	75.4K	61.2K	38.6K	41.2K	37.1K	41.9K
Common Stock Shares Outstanding	11.1M	4.8M	14.7M	19.7M	22.6M	13.6M
Liabilities And Stockholders Equity	696.4K	1.2M	5.8M	9.3M	10.7M	11.2M
Non Current Liabilities Total	2.8M	3.0M	2.8M	2.6M	2.4M	3.6M
Other Current Assets	86.1K	103K	292.0K	298.0K	342.7K	174.8K
Other Stockholder Equity	20.6M	20.6M	42.1M	60.9M	70.0M	73.5M
Total Liab	6.9M	10.2M	5.2M	6.0M	5.4M	6.3M
Net Invested Capital	(5.3M)	(6.9M)	542.4K	3.3M	3.8M	4.0M
Total Current Assets	381.7K	196.7K	5.7M	9.2M	10.6M	11.2M
Accumulated Other Comprehensive Income	(18.7K)	(19.4K)	(151.7K)	(50.8K)	(45.7K)	(48.0K)
Net Working Capital	(3.7M)	(7.0M)	3.3M	5.9M	6.8M	7.1M
Inventory	(33.6K)	(61.2K)	(38.6K)	(41.2K)	(37.1K)	(39.0K)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether NLS Pharmaceutics is a strong investment it is important to analyze NLS Pharmaceutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact NLS Pharmaceutics' future performance. For an informed investment choice regarding NLS Stock, refer to the following important reports:

How To Invest In NLS

Details

Is NLS Stock a good investment?

Details

What is NLS Pharmaceutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NLS Pharmaceutics AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Complementary Tools for NLS Stock analysis

When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.

	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Bonds Directory Find actively traded corporate debentures issued by US companies
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Money Managers Screen money managers from public funds and ETFs managed around the world

Is NLS Pharmaceutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NLS Pharmaceutics. If investors know NLS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NLS Pharmaceutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.50)

Return On Assets

(1.33)

Return On Equity

(8.63)

The market value of NLS Pharmaceutics is measured differently than its book value, which is the value of NLS that is recorded on the company's balance sheet. Investors also form their own opinion of NLS Pharmaceutics' value that differs from its market value or its book value, called intrinsic value, which is NLS Pharmaceutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NLS Pharmaceutics' market value can be influenced by many factors that don't directly affect NLS Pharmaceutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between NLS Pharmaceutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NLS Pharmaceutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NLS Pharmaceutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

NLS Other Assets vs Non Currrent Assets Other Analysis

Other Assets vs Non Currrent Assets Other

Other Assets vs Non Currrent Assets Other Correlation Analysis

Correlation Coefficient

Other Assets

Non Currrent Assets Other

NLS Pharmaceutics fundamental ratios Correlations

NLS Pharmaceutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

NLS Pharmaceutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for NLS Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Long Term Debt	+ 1.0	Short Long Term Debt Total
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash

Other Stockholder Equity	- 0.97	Retained Earnings
Other Stockholder Equity	- 0.97	Net Debt
Non Current Liabilities Total	- 0.97	Other Liab
Long Term Debt	- 0.97	Other Liab
Non Currrent Assets Other	- 0.97	Other Current Liab
Other Liab	- 0.97	Short Long Term Debt Total